Artivion Inc (AORT)vsDexCom Inc (DXCM)
AORT
Artivion Inc
$26.17
-2.71%
HEALTHCARE · Cap: $1.30B
DXCM
DexCom Inc
$82.66
-4.92%
HEALTHCARE · Cap: $31.49B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 983% more annual revenue ($4.97B vs $458.69M). DXCM leads profitability with a 20.1% profit margin vs 2.5%. DXCM appears more attractively valued with a PEG of 1.56. DXCM earns a higher WallStSmart Score of 72/100 (B).
AORT
Hold41
out of 100
Grade: D
DXCM
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-32.5%
Fair Value
$30.26
Current Price
$26.17
$4.09 premium
Intrinsic value data unavailable for DXCM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
17.5% revenue growth
Every $100 of equity generates 31 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.6% — below average capital efficiency
2.5% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 11.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AORT
The strongest argument for AORT centers on Price/Book, Revenue Growth. Revenue growth of 17.5% demonstrates continued momentum.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : AORT
The primary concerns for AORT are EPS Growth, Market Cap, Return on Equity. A P/E of 107.3x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Bear Case : DXCM
The primary concerns for DXCM are PEG Ratio, P/E Ratio, Price/Book.
Key Dynamics to Monitor
AORT profiles as a growth stock while DXCM is a mature play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.45 — expect wider price swings.
AORT is growing revenue faster at 17.5% — sustainability is the question.
DXCM generates stronger free cash flow (449M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 41/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artivion Inc
HEALTHCARE · MEDICAL DEVICES · USA
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?